Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: A systematic review and economic evaluation

Health Technology Assessment

Volumn 16, Issue 23, 2012, Pages 1-137

  Loveman, E ^a   Cooper, K ^a   Bryant, J ^a   Colquitt, J L ^a   Frampton, G K ^a   Clegg, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DIARRHEA; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPEPSIA; DYSPNEA; ECONOMIC EVALUATION; EDEMA; EVENT FREE SURVIVAL; EVIDENCE BASED MEDICINE; FACE EDEMA; FATIGUE; FLUID RETENTION; HEALTH CARE COST; HEMATOLOGY; HUMAN; INFECTION; INFLAMMATION; LEUKOPENIA; LIMB PAIN; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLEURA EFFUSION; PRACTICE GUIDELINE; PROBABILITY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SIDE EFFECT; STANDARDIZATION; STATISTICAL MODEL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, ECONOMIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; THIAZOLES; TREATMENT OUTCOME;

EID: 84863580069     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16230     Document Type: Article

References (27)

1. National Institute for Health and Clinical Excellence (NICE). Imatinib-intolerant chronic myeloid leukemia: dasatinib and nilotinib. Project history. http://guidance.nice.org.uk/TA/Wave17/18#history (accessed 27 January 2011).
2. Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess 2012;16(22).
3. Bristol-Myers Squibb Pharmaceuticals. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (Part Review of TA70). Uxbridge: Bristol-Myers Squibb Pharmaceuticals, UK; 2010.
4. Novartis Pharmaceuticals UK. Nilotinib, within its licensed indications, for the treatment of adults with chronic myeloid leukaemia who are resistant to standard-dose imatinib. Camberley: Novartis, UK; 2010.
5. Dybko J, Medras E, Haus O, Jazwiec J, Duszenko E, Jaskowiec A, et al. Dasatinib is a potent agent in second line treatment for chronic phase chronic myeloid leukemia patients: single center experience. Haematologica 2010;95:542-3.
6. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-50.
7. Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer 2009;115:4136-47.
8. Rajappa S, Mallavarapu KM, Gundeti S, Roshnipaul T, Jacob RT, Digumarti R. Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Leuk Lymphoma 2010;51:79-84.
9. Breccia M, Stagno F, Vigneri P, Latagliata R, Cannella L, Del Fabro V, et al. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. Am J Hematol 2010;85:375-7.
10. Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann Hematol 2010;89:725-31.
11. Baccarani M, Rosti G, Saglio G, Cortes J, Stone R, Niederwieser DW, et al. Dasatinib time to and Durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). ASH Annual Meeting Abstracts 2008;112:450.
12. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 2004;8(36).
13. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press; 2005.
14. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
15. Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib: a Swedish model application. Acta Oncol 2010;49:851-8.
16. Levy AR, Szabo SM, Tabberer M, Davis C. Utility values for health states for chronic myelogenous leukaemia (CML): estimates from laypersons in Australia, The United Kingdom (UK) and Canada. Value Health 2007;10:A283.
17. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-60.
18. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
19. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574-83.
20. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008;26:435-46.
21. Department of Health (DOH). NHS Reference Costs 2006/7. London: DOH; 2008.
22. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-240.
23. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-60.
24. Szabo SM, Levy AR, Davis C, Holyoake TL, Cortes J. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health 2010;13:103-11.
25. Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: a systematic review and economic analysis. Health Technology Assess 2004;8(28).
26. Allan NC, Richards SM, Shepherd PC. Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-7.
27. Centre for Reviews and Dissemination (CRD). Systematic reviews: CRD's guidance for undertaking reviews in health care. 3rd edn. York: York Publishing Services, CRD; 2009.